Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Bevacizumab 47lenvatinib 36atezolizumab 36durvalumab 28tremelimumab 23sintilimab 19Nivolumab 18pembrolizumab 14Radiosurgery 13tislelizumab 11Specimen Handling 10Ipilimumab 10camrelizumab 8apatinib 8Oxaliplatin 8Immune Checkpoint Inhibitors 8Fluorouracil 8Cyclophosphamide 8Blood Specimen Collection 8regorafenib 7cabozantinib 7fludarabine 6Sorafenib 6Radiotherapy 6Magnetic Resonance Spectroscopy 6Leucovorin 6donafenib 5Surgical Procedures, Operative 5Injections 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Hepatocellular × Rosiglitazone × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡